Increased serum GDF11 concentration is associated with a high prevalence of osteoporosis in elderly native Chinese women

Abstract

Osteoporosis is an age-related disease. Many studies have confirmed the anti-aging effect of growth differentiation factor 11 (GDF11), but the action of GDF11 on bone metabolism remains unclear. In this study, we aimed to investigate the relationship between serum GDF11 levels and the prevalence of osteoporosis. Our data indicate negative correlations between serum GDF11 levels and BMD at the lumbar spine and femoral neck. The serum GDF11 levels were grouped into quartile intervals, and the prevalence and risk of osteoporosis were found be markedly greater with increased GDF11 levels. This study demonstrated that GDF11 was negatively correlated with BMD in elderly Chinese women. Furthermore, osteoporotic risk was significantly increased with increases in GDF11 levels.

Circulating GDF11 levels are decreased with age but are unchanged with obesity and type 2 diabetes

“…GDF11 has been shown to decline with aging in mice [15,16,25,26] and other species [25]. In humans, data regarding circulating levels of GDF11 are conflicting showing a decrease [20,27,28], an increase or a trend towards an increase [21-23,29] or no change [22,24,28] with aging. In the present study, the decline in serum GDF11 levels observed in older age was independent of gender and we did not observe differences between genders in GDF11 levels in agreement with previous studies in mice [26] and humans [20].…”

Regulatory Role of RNA N6-Methyladenosine Modification in Bone Biology and Osteoporosis

“…Moreover, Shen et al have reported that FTO was a regulator for BMSCs fate determination during osteoporosis, with a rise in bone marrow in a growth-differentiation factor 11 (GDF11)-C/EBPα-dependent mechanism. Increased serum GDF11 concentration was associated with a high prevalence of osteoporosis by stimulating osteoclastogenesis and inhibiting osteoblast through inducing Smad2/3 phosphorylation (73)(74)(75). Peroxisome proliferator-activated receptor gamma (PPARγ) promoted the adipocyte differentiation and inhibited osteoblast differentiation from BMSCs (76,77).…”

Фактор Диференціації Росту 11: Загальнобіологічні Властивості, Метаболічні Ефекти Та Можлива Патофізіологічна Роль При Артеріальній Гіпертензії, Ожирінні, Цукровому Діабеті Та Залежній Від Віку Патології (Огляд Літератури)

“…GDF11 є універсальним консервативним чинником розвитку тканин для всіх хребетних [13]. GDF11член чинників росту і диференціювання суперсімейства TGF-β 1 /activin/BMP [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43], що активує сигнальні шляхи SMAD (Similar to Mothers Against Decapentaplegic) і non-SMAD і регулює експресію цільових ядерних генів. GDF11 діє як фактор, необхідний для нормального функціонування ембріонального патерну й органогенезу.…”

“…GDF11, відомий також як морфогенетичний кістковий білок 11 (BMP11) [34][35][36][37][38][39], що є протеїном, у людини кодується геном GDF11 і діє як цитокін. BMP11 був відкритий 20 років тому.…”

“…В переліку робот автори [35][36][37][38] показують роль GDF11 у кістковому ремоделюванні. Лікування рекомбінантним GDF11 (rGDF11) призводить до втрати кісткової маси в молодих і старих мишей.…”